R2 updates mammo CAD

AuntMinnie.com staff writers

Jun 2, 2005

Computer-aided detection (CAD) developer R2 Technology has released the latest version of its mammography CAD algorithm. Version 8.0 will be incorporated across R2's ImageChecker product line, and features improved free-response receiver operating characteristics (FROC) performance.

The update provides a lower false marker rate at any given sensitivity -- for example, 1.5 false marks per normal case at the 91 percent sensitivity level, according to the Sunnyvale, CA-based firm.

R2 also expects V8.0 to improve workflow. Its EmphaSize CAD markers draw attention to mammographic features the algorithm regards as characteristic of malignancy, while its Greenlight user interface helps technologists process films quickly and monitor the progress of the film scanning from a distance, R2 said.

By AuntMinnie.com staff writers
June 3, 2005

Related Reading

R2 debuts ImageChecker 2.0 for CT, May 17, 2005

R2 adds to executive lineup, May 13, 2005

iCAD, R2 in patent dispute, April 28, 2005

Vital Images, R2 form alliance, April 26, 2005

R2 gets FDA nod for CAD with Mammomat, February 23, 2005

Copyright © 2005 AuntMinnie.com

Images in a 70-year-old asymptomatic woman with a prior excisional biopsy in the left breast yielding lobular carcinoma in situ 3 years earlier. Screening contrast-enhanced mammography (CEM) was performed, which was considered a prevalence screen as the woman had no prior breast MRI in the past 3 years and no prior CEM. (A) Low-energy (26–30 kVp) mediolateral oblique (MLO) and (B) craniocaudal (CC) views show surgical clips but no abnormality. (C) Recombined MLO and (D) CC images show an enhancing mass in the medial left breast (arrows). Biopsy revealed invasive lobular carcinoma. Size was 0.2 cm; tumor grade II/III; negative lymph nodes; and estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative.

CEM finds breast cancer at baseline, incidence screening

July 28, 2026

Minnie Cast Thumbnail (15)

Women's Imaging MinnieCast, Episode 13: Partial breast irradiation in the spotlight

July 17, 2026

A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.

Incorrect AI suggestions influence reader performance on mammography

July 14, 2026

Mammogram Calendar 400

Breast cancer screening higher among civically engaged women

July 14, 2026

CEM finds breast cancer at baseline, incidence screening

By Amerigo Allegretto

Incidence screening with CEM maintains high performance and may offer more benefits over baseline CEM screening.

July 28, 2026

Images in a 70-year-old asymptomatic woman with a prior excisional biopsy in the left breast yielding lobular carcinoma in situ 3 years earlier. Screening contrast-enhanced mammography (CEM) was performed, which was considered a prevalence screen as the woman had no prior breast MRI in the past 3 years and no prior CEM. (A) Low-energy (26–30 kVp) mediolateral oblique (MLO) and (B) craniocaudal (CC) views show surgical clips but no abnormality. (C) Recombined MLO and (D) CC images show an enhancing mass in the medial left breast (arrows). Biopsy revealed invasive lobular carcinoma. Size was 0.2 cm; tumor grade II/III; negative lymph nodes; and estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative.

Women's Imaging MinnieCast, Episode 13: Partial breast irradiation in the spotlight

By Amerigo Allegretto

Two committee members for ASTRO's PBI guidelines share insights about this breast cancer treatment option.

July 17, 2026

Minnie Cast Thumbnail (15)

Incorrect AI suggestions influence reader performance on mammography

By Amerigo Allegretto

The biggest impact on reader performance stemmed from false-negative AI suggestions.

July 14, 2026

A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.

Breast cancer screening higher among civically engaged women

By Amerigo Allegretto

Women who voted, attended a public meeting, or volunteered are more likely to get their breast cancer screening.

July 14, 2026

Mammogram Calendar 400

CEM on par with MRI for breast cancer diagnosis, local staging

By Amerigo Allegretto

CEM alone in a prospective study achieved perfect sensitivity and negative predictive value in diagnosing breast cancer.

July 10, 2026

MRI false positive for additional disease, (top to bottom): A. Index lesion—grade 2 invasive ductal carcinoma; B. MRI lesion two, upper inner quadrant: Stromal sclerosis and columnar cell change; C. MRI lesion three, upper outer quadrant: No ultrasound correlate, no malignancy on follow-up; D. CEM marked background parenchymal enhancement with a unifocal retroareolar lesion demonstrating wash-out on delayed MLO. Images are republished under a Creative Commons license (CC BY 4.0).

Siemens Healthineers gets FDA nod for CEM on Mammomat B.brilliant

By AuntMinnie.com staff writers

Siemens Healthineers has received FDA clearance for CEM and CEM biopsy capabilities for its Mammomat B.brilliant system.

June 30, 2026

Mammomat B.brilliant breast imaging system

Fujifilm, IAEA sign agreement to expand cancer imaging

By AuntMinnie.com staff writers

The two organizations will collaborate on awareness campaigns, education and training programs for healthcare professionals, and the provision of Fujifilm medical equipment.

June 29, 2026

DeepHealth gets FDA nod for two mammography AI tools

By AuntMinnie.com staff writers

DeepHealth has received FDA clearance for two parts of the company's Breast Suite AI platform: BAC Assessment and Mammo Dx.

June 25, 2026

Deephealth White On Purple

QT Imaging reports low variability for breast scanner biomarkers

By AuntMinnie.com staff writers

Study analyzes Breast Acoustic CT speed-of-sound (SoS) measurements.

June 24, 2026

Breast Update 2 T76 Vuzvgq

Komen awards $15.4 million in breast cancer research grants

By AuntMinnie.com staff writers

Susan G. Komen has awarded over $15 million in grant funding toward breast cancer research.

June 23, 2026

Research Money 400

PET/CT could improve margin assessment for breast tumors

By Amerigo Allegretto

Specimen PET/CT imaging outperforms routine intraoperative margin assessment in breast tumors.

June 19, 2026

Pet Scan Patient 400 (1)

AI may provide early breast cancer alerts from mammograms

By Amerigo Allegretto

Commercial AI systems could provide early alerts for breast cancer by picking out early signs of the disease on mammograms.

June 9, 2026

Screening mammograms and AI score changes are depicted over time in two individuals with screen-detected cancer. Full-field digital mammograms show craniocaudal (top) and mediolateral (bottom) views of the left and right breast. The description below each mammogram indicates whether AI scores from three AI-based computer-aided detection systems (AI-1, AI-2, and AI-3) were above or below the 90th percentile. (A) Mammograms from three screening time points (in 2009, 2011, and 2014) in an individual who was diagnosed in February 2014 (at age 73 years) with a left-sided 25-mm grade 2 invasive breast carcinoma, no special type (arrow). Mammographic breast density was classified as BI-RADS B on all three mammograms. (B) Mammograms from four screening time points (in 2009, 2011, 2013, and 2015) in an individual who was diagnosed in October 2015 (at age 65 years) with a left-sided 45-mm grade 2 lobular carcinoma (arrow). Mammographic breast density was classified as BI-RADS C on all four mammograms. Screen-detected cancers were defined as those diagnosed within 90 days for individuals who were recalled at screening (*).

Page 1 of 583